35127778|t|Effects of Docosahexanoic Acid on Gut Microbiota and Fecal Metabolites in HIV-Infected Patients With Neurocognitive Impairment: A 6-Month Randomized, Double-Blind, Placebo-Controlled Trial.
35127778|a|Neurocognitive impairment (NCI) and gut microbiota dysbiosis are prevalent in patients with HIV infection. Docosahexanoic acid (DHA) supplementation may alleviate multiple neurocognitive diseases symptoms and plays important role in regulating gut microbiota. However, it is not known whether DHA algae oil supplements can alleviate neurocognitive impairment (NCI) and regulate gut microbiota and fecal metabolites. A randomized, double-blind, placebo-controlled trial was performed on 68 HIV-infected patients with NCI. Participants were randomized to receive a 3.15 g daily DHA algae oil supplement or placebo for 6 months. We collected blood and fecal samples from these patients before and after the trial. Mini mental state examination (MMSE) and neuropsychological tests (NP tests) were administered to assess the cognitive status of participants. The influence of DHA algae oil on the gut microbiota, fecal metabolomics, plasma proinflammatory, and oxidative stress factors was also investigated. There were no significant changes in NCI according to global diagnosis score (GDS) and MMSE score within the two groups, while patients receiving DHA had improvement in several blood lipids, pro-inflammatory and oxidative stress factors. The DHA supplement increased alpha-diversity indexes, increased abundances of Blautia, Bifidobacterium, Dorea, Lactobacillus, Faecalibacterium, Fusobacterium, and Agathobacter, and decreased abundances of Bacteroides and Prevotella_9. Furthermore, DHA supplement was correlated with improved fecal lipid metabolites as indicated by ceramides, bile acids, glycerophospholipids. In addition, the DHA supplement was associated with altered cholesterol metabolism and purine metabolism pathways. A daily supplement of DHA algae oil for 6 months has been shown to promote favorable transformations in gut microbiota, profiles of fecal metabolomic, and factors responsible for proinflammatory and oxidative stress, which might be beneficial for the prognosis of HIV-infected patients with NCI in the long-term. CLINICAL TRIAL REGISTRATION: https://clinicaltrials.gov/ct2/show/NCT04242004, identifier: NCT04242004.
35127778	11	30	Docosahexanoic Acid	Chemical	MESH:D004281
35127778	74	86	HIV-Infected	Disease	MESH:D015658
35127778	87	95	Patients	Species	9606
35127778	101	126	Neurocognitive Impairment	Disease	MESH:D019965
35127778	190	215	Neurocognitive impairment	Disease	MESH:D019965
35127778	217	220	NCI	Disease	MESH:D019965
35127778	230	250	microbiota dysbiosis	Disease	MESH:D064806
35127778	268	276	patients	Species	9606
35127778	282	295	HIV infection	Disease	MESH:D015658
35127778	297	316	Docosahexanoic acid	Chemical	MESH:D004281
35127778	318	321	DHA	Chemical	MESH:D004281
35127778	362	385	neurocognitive diseases	Disease	MESH:D004194
35127778	483	496	DHA algae oil	Chemical	-
35127778	523	548	neurocognitive impairment	Disease	MESH:D019965
35127778	550	553	NCI	Disease	MESH:D019965
35127778	679	691	HIV-infected	Disease	MESH:D015658
35127778	692	700	patients	Species	9606
35127778	706	709	NCI	Disease	MESH:D019965
35127778	766	779	DHA algae oil	Chemical	-
35127778	864	872	patients	Species	9606
35127778	1061	1074	DHA algae oil	Chemical	-
35127778	1125	1140	proinflammatory	Disease	
35127778	1231	1234	NCI	Disease	MESH:D019965
35127778	1321	1329	patients	Species	9606
35127778	1340	1343	DHA	Chemical	MESH:D004281
35127778	1377	1383	lipids	Chemical	MESH:D008055
35127778	1389	1401	inflammatory	Disease	MESH:D007249
35127778	1436	1439	DHA	Chemical	MESH:D004281
35127778	1519	1534	Bifidobacterium	Species	1678
35127778	1543	1556	Lactobacillus	Species	1578
35127778	1558	1574	Faecalibacterium	Species	216851
35127778	1576	1589	Fusobacterium	Species	848
35127778	1595	1607	Agathobacter	Species	1766253
35127778	1637	1648	Bacteroides	Species	816
35127778	1653	1665	Prevotella_9	Species	
35127778	1680	1683	DHA	Chemical	MESH:D004281
35127778	1730	1735	lipid	Chemical	MESH:D008055
35127778	1764	1773	ceramides	Chemical	MESH:D002518
35127778	1775	1785	bile acids	Chemical	MESH:D001647
35127778	1787	1807	glycerophospholipids	Chemical	MESH:D020404
35127778	1826	1829	DHA	Chemical	MESH:D004281
35127778	1869	1880	cholesterol	Chemical	MESH:D002784
35127778	1896	1902	purine	Chemical	MESH:C030985
35127778	1946	1959	DHA algae oil	Chemical	-
35127778	2103	2118	proinflammatory	Disease	
35127778	2188	2200	HIV-infected	Disease	MESH:D015658
35127778	2201	2209	patients	Species	9606
35127778	2215	2218	NCI	Disease	MESH:D019965
35127778	Association	MESH:D002784	MESH:D004281
35127778	Association	MESH:D001647	MESH:D004281
35127778	Association	MESH:D004281	MESH:D020404
35127778	Negative_Correlation	MESH:D004281	MESH:D019965
35127778	Positive_Correlation	MESH:D002518	MESH:D004281
35127778	Negative_Correlation	MESH:D004281	MESH:D008055
35127778	Negative_Correlation	MESH:D004281	MESH:D007249
35127778	Association	MESH:C030985	MESH:D004281
35127778	Negative_Correlation	MESH:D004281	MESH:D004194

